Atlas Trials

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Clinical trial NCT04024228 · COMPLETED

Trial details

NCT number
NCT04024228
Sponsor
Sanofi Pasteur, a Sanofi Company
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Influenza ImmunizationHealthy Volunteers
Start date
2019-10-28
Primary completion
2020-01-09
Enrollment
1539

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.